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MaLittle is known about the beneﬁts and risks of the long-term use of cardiovascular drugs. Evidence from randomized
clinical trials (RCTs) rarely goes beyond a few years of follow-up, but patients are often given continuous treatment with
multiple drugs well into old age. We focus on 4 commonly used cardiovascular drug classes: aspirin, statins, beta-
blockers, and angiotensin-converting enzyme inhibitors given to patients after myocardial infarction. However, the issues
raised apply more broadly to all long-term medications across cardiovascular diseases and the whole of medicine. The
evidence and limitations of RCTs are addressed, as well as current practice in pre-licensing trials, the increasing problems
of polypharmacy (especially in the elderly), the lack of trial evidence for withdrawal of drugs, the role of regulatory
authorities and other stakeholders in this challenging situation, and the potential educational solutions for the
medical profession. We conclude with a set of recommendations on how to improve the situation of long-term drug use.
(J Am Coll Cardiol 2015;66:1273–85) © 2015 by the American College of Cardiology Foundation.W orldwide, millions of patients with coro-nary heart disease (CHD) have beenreceiving cardiovascular drugs for de-
cades, in the absence of any evidence from clinical
trials to justify their use beyond 5 to 10 years (1–5).
Although there is abundant evidence of the value of
4 groups of drugs (aspirin, beta-blockers, statins,
and angiotensin-converting enzyme [ACE] inhibitors)
in the prevention and treatment of CHD in the ﬁrst
few years after an acute coronary event (1–5), there
is inadequate evidence for the continuation of these
drugs beyond that time. Additional concerns have
arisen with the introduction of the ﬁxed-dose polypill
as a potential life-long therapy.
Our attention was drawn to this issue by the
personal experience of 1 of the investigators (6). He
developed an episode of severe hypotension during
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>15 years, cough from an ACE inhibitor after being on
ramipril for 10 years, and aspirin-induced gastroin-
testinal bleeding after being on the drug for 20 years.
We suspect such risks are not uncommon. The 2
episodes due to the beta-blocker could have been
fatal if immediate help had not been available, and
the death would not have been attributed to the drug.
Therefore, we feel it is important to challenge the
assumption that the efﬁcacy and safety of drugs given
in the relatively short term remain the same over the
long term and into old age.
In the following sections, Aspirin, Statins,
Beta-Blockers, and Angiotensin-Converting Enzyme
Inhibitors After Myocardial Infarction and The
Knowledge Gap in Long-Term Use of Cardiovascular
Drugs, we summarize the evidence and the gaps of
knowledge with the regard to the use of aspirin,IC), Madrid, Spain; yHatter Cardiovascular Institute,
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ABBR EV I A T I ON S
AND ACRONYMS
ACC = American College of
Cardiology
ACE = angiotensin-converting
enzyme
ACS = acute coronary
syndrome
AHA = American Heart
Association
ARB = angiotensin receptor
blocker
CHD = coronary heart disease
EMA = European Medicines
Agency
FDA = Food and Drug
Administration
MI = myocardial infarction
PCI = percutaneous coronary
intervention
RCT = randomized clinical trial
STEMI = ST-segment elevation
myocardial infarction
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after myocardial infarction (MI). The section
on Problems With Current Practice in Pre-
Licensing Trials explains how the regulatory
environment inﬂuences the current practice
of pre-licensing trials. We then tackle the
increasing problems of polypharmacy, espe-
cially in the elderly, in the Problems of Pol-
ypharmacy section; of the long-term use of
cardiovascular drugs in Long-Term Use of
Medications and Aging; and the lack of trial
evidence for withdrawal of drugs in the
Deprescribing section. We propose a poten-
tial randomized trial in the section called An
Example Randomized Clinical Trial for
Withdrawal of Beta-Blockers. The section on
Responsibilities of Regulators and Other
Stakeholders considers the responsibilities of
the regulating authorities and other stake-
holders facing this challenge and the poten-
tial educational solutions for the medical
profession. The Recommendations section
provides a concluding set of recommenda-tions to improve the situation. The Central Illustration
depicts the content of the review.
ASPIRIN, STATINS, BETA-BLOCKERS,
AND ANGIOTENSIN-CONVERTING
INHIBITORS AFTER MI
CHD is a chronic condition that includes patients with
and without previous MIs. Secondary prevention
interventions reduce the risk for new cardiovascular
events in patients with established CHD. By way of
example, we report the biological effects and the
main evidence regarding the 4 drugs most commonly
used in cardiology: aspirin, statins, beta-blockers,
and ACE inhibitors. We also summarize the guide-
lines’ recommendations for each drug (Table 1 [7–9]).
Aspirin decreases platelet aggregation and prevents
formation of coronary thrombus. Aspirin reduces the
risk of both re-infarction and vascular death in post-MI
patients (10). According to the guidelines (7), aspirin
should be prescribed indeﬁnitely after MI. Despite the
strong evidence supporting the absolute risk reduc-
tion of thrombotic events with the use of aspirin
in secondary prevention, the tradeoff between the
beneﬁts and the risk of bleeding events is less clear in
some particular settings, such as in the elderly.
Statins are effective in reducing low-density lipo-
protein cholesterol. After an ST-segment elevation
myocardial infarction (STEMI), statins lower the risk
of cardiovascular death, recurrent MI, stroke, and
the need for coronary revascularization (11,12). TheAmerican College of Cardiology (ACC)/American
Heart Association (AHA) guidelines recommend that
high-dose statin therapy should be initiated or
continued in all patients with STEMI with no contrain-
dication to its use. It is implied that continuation is
long-term. Statins are also widely used for primary
prevention, and although they seem to be cost-effective
therapy, concerns have arisen regarding an increase in
geriatric-speciﬁc adverse effects (13) and the potential
of the increased incidence of diabetes (14).
Beta-blockers prevent the action of endogenous
catecholamines, and consequently, lower heart rate
and blood pressure. Beta-blocker treatment after MI
is associated with reduced mortality and morbidity
(5). Patients with MI complicated by heart failure, left
ventricular dysfunction, or ventricular arrhythmias
receive the greatest beneﬁt of this therapy (7). The
value (or not) of long-term duration of routine beta-
blocker therapy after uncomplicated MI has not
been investigated. In the AHA/ACC Foundation sec-
ondary prevention guidelines (15), beta-blocker ther-
apy is recommended to last for 3 years in all patients
with normal left ventricular function who have had a
MI. It is unclear what should happen beyond 3 years.
ACE inhibitors act by blocking the renin–
angiotensin system, and have been shown to reduce
fatal and nonfatal cardiovascular events in patients
with STEMI (16). However, although the clinical
beneﬁt is well established in high-risk subgroups,
such as patients with anterior MI, ejection fractions
of <40%, heart failure, previous MI, or tachycardia
(7), the role of routine long-term ACE inhibitor
therapy in low-risk patients after STEMI is less certain
(4,17,18). Current ACC/AHA guidelines declare that
ACE inhibitors are reasonable for all STEMI patients,
with no contraindications to their use.
Once initiated, there is no clear evidence for how
long these 4 drugs should be prescribed. Additional
concerns have arisen with the introduction of the
ﬁxed-dose polypill as potential life-long therapy in
post-MI patients (19,20). Although we concentrate on
post-MI patients, including those with STEMI and
non-STEMI, these problems and the uncertainties
regarding long-term drug use may also apply to other
cardiac diseases (e.g., heart failure, atrial ﬁbrillation)
and in the primary prevention setting.
THE KNOWLEDGE GAP IN LONG-TERM USE
OF CARDIOVASCULAR DRUGS
Clinicians or those writing guidelines have given little
consideration to the use of drugs over decades, and
trialists have used “long-term” to mean “not very
short-term.” Thus, in a recent publication of a
CENTRAL ILLUSTRATION Long-Term Use of Cardiovascular Drugs:
Challenges for Research and for Patient Care
CONCERNS WITH CURRENT LONG-TERM USE OF CARDIOVASCULAR DISEASE DRUGS
Unclear guidelines for drug use after myocardial infarction
• Health care providers/physicians need better guidance for 
long-term use of Aspirin, Statin, Beta-blockers and ACE inhibitors
• Once initiated, no evidence for how long these drugs should be prescribed
Knowledge gap regarding long-term use
• RCTs provide relatively short-term follow-up
• RCTs prior to primary PCI are outdated
• Efficacy/safety trade-off may change, especially in the elderly
Problems with pre-licensing RCTs
• Successful drugs are added to standard of care, increasing polypharmacy
• Lack of head-to-head trials
Problems with polypharmacy
• Patients often on multiple drugs, long-term
• Deprescribing policies need objective evidence
Long-term medication in the elderly
• Aging, co-morbidities and frailty affect drug safety and efficacy
• Older patients under-represented in RCTs
Lack of drug withdrawal trials
• A need to investigate drug withdrawal as alternative
to long-term continuation of drugs
Rossello, X. et al. J Am Coll Cardiol. 2015; 66(11):1273–85.
Summary of our concerns regarding current long-term use of cardiovascular drugs.
ACE ¼ angiotensin-converting enzyme; PCI ¼ percutaneous coronary intervention;
RCTs ¼ randomized clinical trials.
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1275randomized clinical trial (RCT) in post-MI patients,
PEGASUS-TIMI 54 (Prevention of Cardiovascular
Events in Patients With Prior Heart Attack Using
Ticagrelor Compared to Placebo on a Background of
Aspirin-Thrombolysis In Myocardial Infarction 54)
(21), the expression “long-term use” in the title
referred to a median 33 months of follow-up. Even
more disturbingly, a recent real-world Swedish reg-
istry in post-MI patients (22) deﬁned a long-term
perspective as 1 year of follow-up. Beyond these
terminology issues, these studies reﬂect the propor-
tion of post-MI patients taking cardiovascular drugs.
In the RCT, the percentages of patients taking medi-
cations 1 to 3 years after a MI were as follows: aspirin,
100%; statin, 93%; beta-blocker, 82%; and ACE
inhibitor or angiotensin receptor blocker (ARB), 80%.
In the registry, the percentages of patients on medi-
cations at 1-year of follow-up were: aspirin, 82%;
statin, 73%; beta-blocker, 80%; and ACE inhibitor or
ARB, 75%. However, our use of long-term relates to
much longer periods; real-world, post-MI patients
may well stay on such drugs for decades, although
there is no direct evidence that this is beneﬁcial.
Current treatment of survivors of acute MI is based
on the results of large RCTs and subsequent meta-
analyses. These have demonstrated that aspirin,
beta-blockers, ACE inhibitors, and statins improve
prognosis after an acute MI. Although RCTs provide
the highest level of evidence for assessing the efﬁcacy
and safety of a drug, there are some limitations with
regard to the extrapolation of their results to the
seriously long-term usage of these drugs.
The key limitation is a gap of knowledge between
the short-term evidence and the long-termuse of these
drugs. Although the average follow-up in RCTs is
limited, these medications are often administered
open-endedly overmany years. Table 2 (11,12,17,23–49)
shows an overview of some landmark RCTs that
demonstrated the efﬁcacy of aspirin, statins, beta-
blockers, and ACE inhibitors in post-MI (and stable
CHD) patients. A good example of this problem is a
meta-analysis published in 2010 on the use of statins as
primary and secondary prevention, in which the me-
dian follow-up across 26 trials was 4.9 years (2). Amore
extreme case is seen with beta-blockers after MI;
a meta-analysis published in 1999 (5) had a mean
follow-up across 82 RCTs of only 1.4 years.
A second gap between evidence and real-world
practice is that the recommended long-term use of
these drugs is based implicitly on a constant rela-
tive hazard assumption, meaning that the beneﬁts
continue (and stay constant) over the long-term,
when no data exist to conﬁrm or refute this pre-
sumption. It is important to consider how theabsolute risk changes over time. Many trials started
follow-up in the post-acute phase of acute coronary
syndrome (ACS), when the risk is high, and therefore,
the beneﬁt may be greatest. Survivors several years
after an MI may be a relatively low-risk cohort, so
absolute beneﬁts may be relatively small. In the truly
long term, the risks of major cardiac events and death
increases with age, but whether these medications
beneﬁt elderly patients long after the initial MI
remains without assurance by RCTs.
In a pre-reperfusion era meta-analysis (16), ACE
inhibitors started in the acute phase of MI showed an
early absolute beneﬁt of 5 lives saved per 1,000
patients treated in the ﬁrst month. Even more
importantly, this meta-analysis showed that most
of this beneﬁt was markedly reduced over the sub-
sequent 3 years.
TABLE 1 Summary of ACC/AHA Guidelines Regarding Use of Aspirin, Statins, Beta-Blockers, and ACE Inhibitors*
Aspirin
STEMI After PCI, aspirin should be continued indeﬁnitely (Class I, Level of Evidence: A)
NSTEMI Aspirin should be continued indeﬁnitely. The maintenance dose should be 81 mg daily in patients treated with ticagrelor and 81 to 325 mg daily in all
other patients (Class I, Level of Evidence: A)
SIHD Treatment with aspirin 75 to 162 mg daily should be continued indeﬁnitely in the absence of contraindications in patients with SIHD
(Class I, Level of Evidence: A)
Statins
STEMI High-intensity statin therapy should be initiated or continued in all patients with STEMI and no contraindications to its use (Class I, Level of Evidence: B)
NSTEMI High-intensity statin therapy should be initiated or continued in all patients with NSTE-ACS and no contraindications to its use (Class I, Level of Evidence: B)
SIHD In addition to therapeutic lifestyle changes, a moderate or high dose of a statin therapy should be prescribed, in the absence of contraindications or
documented adverse effects (Class I, Level of Evidence: A)
Beta-blocker therapy
STEMI Oral beta-blockers should be initiated in the ﬁrst 24 h in patients with STEMI who do not have any of the following: signs of heart failure; evidence of a low
output state; increased risk for cardiogenic shock; or other contraindications to use of oral beta-blockers (PR interval >0.24 s, second- or third-degree
heart block, active asthma, or reactive airway disease) (Class I, Level of Evidence: B)
Beta-blockers should be continued during and after hospitalization for all patients with STEMI and with no contraindications to their use
(Class I, Level of Evidence: B)
NSTEMI Oral beta-blocker therapy should be initiated within the ﬁrst 24 h in patients who do not have any of the following: 1) signs of HF; 2) evidence of
low-output state; 3) increased risk for cardiogenic shock; or 4) other contraindications to beta-blockade (e.g., PR interval >0.24 s, second- or
third-degree heart block without a cardiac pacemaker, active asthma, or reactive airway disease) (Class I, Level of Evidence: A)
It is reasonable to continue beta-blocker therapy in patients with normal LV function with NSTE-ACS (Class IIa, Level of Evidence: C)
SIHD Beta-blocker therapy should be started and continued for 3 yrs in all patients with normal LV function after MI or ACS (Class I, Level of Evidence: B)
Beta-blocker therapy should be used in all patients with LV systolic dysfunction (EF <40%) with HF or previous MI, unless contraindicated
(Class I, Level of Evidence: A)
Beta-blockers may be considered as long-term therapy for all other patients with coronary or other vascular disease (Class IIb, Level of Evidence: C)
ACE inhibitors
STEMI An ACE inhibitor should be administered within the ﬁrst 24 h to all patients with STEMI with an anterior location, HF, or EF #40%, unless contraindicated
(Class I, Level of Evidence: A)
ACE inhibitors are reasonable for all patients with STEMI and no contraindications to their use (Class IIa, Level of Evidence: A)
NSTEMI ACE inhibitors should be started and continued indeﬁnitely in all patients with LVEF <0.40 and in those with hypertension, diabetes mellitus, or stable
CKD, unless contraindicated (Class I, Level of Evidence: A)
ACE inhibitors may be reasonable in all other patients with cardiac or other vascular disease (Class IIb, Level of Evidence: C)
SIHD ACE inhibitors should be prescribed in all patients with SIHD who also have hypertension, diabetes mellitus, LVEF #40%, or CKD, unless contraindicated
(Class I, Level of Evidence: A)
Treatment with an ACE inhibitor is reasonable in patients with both SIHD and other vascular disease (Class IIa, Level of Evidence: B)
Each statement is presented with the class of recommendation and level of evidence in brackets. *Recommendations from O’Gara et al. (7), Fihn et al. (8), and Amsterdam et al. (9).
ACC ¼ American College of Cardiology; ACE ¼ angiotensin-converting enzyme; ACS ¼ acute coronary syndrome; AHA ¼ American Heart Association; CKD ¼ chronic kidney disease; EF ¼ ejection fraction;
HF ¼ heart failure; LV ¼ left ventricle/ventricular; LVEF ¼ left ventricular ejection fraction; MI ¼ myocardial infarction; NSTE-ACS ¼ non–ST-segment elevation acute coronary syndrome; NSTEMI ¼ non–ST-
segment elevation myocardial infarction; PCI ¼ percutaneous coronary intervention; SIHD ¼ stable ischemic heart disease; STEMI ¼ ST-segment elevation myocardial infarction.
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cutaneous coronary intervention (PCI), risks change
rapidly over time; cardiac mortality is high (>7%)
during the ﬁrst month, but subsequently falls
to <1.5% year. Also, the cause of death after STEMI is
mainly cardiac in the ﬁrst 5 years, but noncardiac
mortality becomes more important later (50).
A third limitation of evidence from RCTs is the
change in practice over time. Many trials were per-
formed in the ﬁbrinolytic era, whereas current wide-
spread use of primary PCI (reperfusion therapy) has
had an impact on long-term prognosis, and may well
affect the value of post-MI medications. For instance,
the evidence regarding beta-blocker use after MI is
mostly derived from trials conducted in the pre-
reperfusion era. In 1 meta-analysis (5) cited in the
2013 ACC/AHA Guideline for the Management of ST-
Elevation Myocardial Infarction, the median publica-
tion date of the 82 beta-blocker RCTs included was
1982. Moreover, most of these trials were performedbefore the implementation of other secondary pre-
vention therapies, such as statins and ACE inhibitors.
Thus, controversy exists over the role of beta-blockers
after primary PCI. In the absence of relevant RCTs,
observational studies are contradictory; 1 that showed
treatment with beta-blockers after successful primary
PCI was associated with reduced 6-month mortality
(51), whereas another demonstrated no reduction of a
composite of cardiovascular events with the use of
beta-blockers after MI (52).
The universal deﬁnition of MI has changed 3 times
between 2000 and 2012 (53–55), which is a further
complication, making a lower risk cohort progres-
sively eligible for RCTs in real-world practice, when
these patients would not have been included in RCTs
using previous deﬁnitions.
Another limitation is the difﬁculty in extrapolating
RCT results to the real world. For example, the
average age of patients included in MI trials tends to
be younger than the typical MI patient; there is often
TABLE 2 Summary of the Main RCTs Regarding Use of Aspirin, Statins, Beta-Blockers, and ACE Inhibitors in Secondary Prevention
Study (Ref. #)
Year
Published
No. of
Participants
Mean Follow-Up
(yrs)
Age Range
(yrs)
Mean Age
(yrs) Eligible Population
Placebo-
Controlled Drug
Aspirin
Cardiff-I (23) 1974 1,239 1 NR 55 Post-MI Yes Aspirin
CDP-A (24) 1976 1,529 1.8 NR 56 Post-MI Yes Aspirin
Cardiff-II (25) 1979 1,682 1 NR 56 Post-MI Yes Aspirin
PARIS (26) 1980 1,216 3.4 30–74 56 Post-MI Yes Aspirin and persantine
AMIS (27) 1980 4,524 >3 30–69 55 Post-MI Yes Aspirin
Statins
4S (12) 1994 4,444 5.4 35–70 NR History of angina or MI Yes Simvastatin
CARE (11) 1996 4,159 5 21–75 59 Post-MI Yes Pravastatin
LIPID (28) 1998 9,014 6.1 31–75 62 Post-MI or UA Yes Pravastatin
GISSI-P (29) 2000 4,271 2 19–90 60 Post-MI Yes Pravastatin
LIPS (30) 2002 1,677 3.9 18–80 60 Post-PCI Yes Fluvastatin
ALLIANCE (31) 2004 2,442 4.5 $18 61 CHD Yes Atorvastatin
PROVE IT (32) 2004 4,162 2 $18 58 Post-ACS No Pravastatin and atorvastatin
A to Z (33) 2004 4,497 2 21–80 61 Post-ACS No Simvastatin (low vs. high dose)
TNT (34) 2005 10,001 4.9 35–75 61 CHD No Atorvastatin (low vs. high dose)
IDEAL (35) 2005 8,888 4.8 #80 62 Post-MI No Atorvastatin and Simvastatin
SEARCH (36) 2010 12,064 6.7 18–80 64 Post-MI No Simvastatin (low vs. high dose)
Beta-blockers
Multicenter International (37) 1975 3,038 Up to 3 #70 55 Post-MI Yes Practolol
Julian et al. (38) 1982 1,456 1 30–69 55 Post-MI Yes Sotalol
EIS (39) 1984 1,741 1 35–69 54 Post-MI Yes Oxprenolol
Salathia et al. (40) 1985 800 1 NR NR Suspected MI Yes Metoprolol
LIT (41) 1987 2,395 1.6 45–74 58 Post-MI Yes Metoprolol
CAPRICORN (42) 2001 1,959 1.3 $18 63 Post-MI with LV dysfunction Yes Carvedilol
ACE inhibitors
SAVE (43) 1992 2,231 3.5 21–80 59 Post-MI and LV dysfunction Yes Captopril
TRACE (44) 1995 1,749 2–4.2 $18 67 Post-MI and LV dysfunction Yes Trandolapril
AIRE (45) 1993 2,006 1.3 $18 65 Post-MI with HF Yes Ramipril
ISIS-4 (46) 1995 58,050 1.3 NR NR Suspected MI Yes Captopril, mononitrate, and
magnesium sulfate
QUIET (47) 2001 1,725 2.25 18–75 58 Post-PCI or atherectomy Yes Quinapril
CAMELOT (48) 2004 1997 2 30–79 57 CHD No Enalapril and amlodipine
EUROPA (49) 2003 12,218 4.2 $18 60 SIHD without HF Yes Perindopril
PEACE (17) 2004 8,290 4.8 $50 64 SIHD and preserved LV function Yes Trandolapril
This table is based on the most comprehensive published meta-analyses (1–5), and includes randomized clinical trials (RCTs) with >1,000 patients and >1-year follow-up.
4S ¼ Scandinavian Simvastatin Survival Study; A to Z ¼ Combined use of low-molecular-weight heparin with the glycoprotein IIb/IIIa inhibitor tiroﬁban and efﬁcacy of early aggressive simvastatin therapy;
AIRE ¼ Acute Infarction Ramipril Efﬁcacy; ALLIANCE ¼ Aggressive Lipid-Lowering Initiation Abates New Cardiac Events study; AMIS ¼ Aspirin Myocardial Infarction Study; CAMELOT ¼ Comparison of
Amlodipine vs Enalapril to Limit Occurrences of Thrombosis; CAPRICORN¼ Carvedilol Post-Infarct Survival Control in LV Dysfunction; CARE ¼ Cholesterol and Recurrent Event; CHD¼ coronary heart disease;
CDP-A ¼ Coronary Drug Project Aspirin Study; EIS ¼ European Infarction Study; EUROPA ¼ EURopean trial On reduction of cardiac events with Perindopril in stable coronary Artery disease; GISSI-P ¼ Gruppo
Italiano per lo Studio della Sopravvivenza nell’Infarto Miocardico-Prevenzione; IDEAL ¼ Incremental Decrease in End Points Through Aggressive Lipid Lowering; ISIS-4 ¼ Fourth International Study of Infarct
Survival; LIPID ¼ Long-Term Intervention with Pravastatin in Ischaemic Disease; LIPS ¼ Lescol Intervention Prevention Study; LIT ¼ Lopressor Intervention Trial; NR ¼ not reported; PARIS ¼ Persantine-
Aspirin Reinfarction Study; PEACE ¼ Prevention of Events with Angiotensin Converting Enzyme Inhibition; PROVE IT ¼ Pravastatin or Atorvastatin Evaluation and Infection Therapy–Thrombolysis in
Myocardial Infarction; QUIET ¼ QUinapril Ischemic Event Trial; SAVE ¼ Survival and Ventricular Enlargement Trial; SEARCH ¼ Study of the Effectiveness of Additional Reductions in Cholesterol and Ho-
mocysteine; TNT ¼ Treating to New Targets; TRACE ¼ Trandolapril Cardiac Evaluation; UA ¼ unstable angina; other abbreviations as in Table 1.
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elderly patients in cardiovascular RCTs (56). This
issue will be covered in the section on Deprescribing.
Also, the net beneﬁt of some medications may
be neutralized with the appearance of age-related
adverse effects and comorbidities (drug–disease and
drug–drug interactions), which are not well studied in
RCTs. This issue is discussed in the section on Long-
Term Use of Medications and Aging.In principle, we need RCTs of post-MI medications
to be extended into truly long-term follow-up.
However, in practice, to achieve trials with >5 years
follow-up is a major challenge, not just because of
increased noncompliance and loss to follow-up, but
also due to the increased costs of organizing and
monitoring long-term follow-up. Thus, to ﬁll the
evidence gaps on long-term effectiveness and safety
issues regarding cardiovascular drug use, and despite
Rossello et al. J A C C V O L . 6 6 , N O . 1 1 , 2 0 1 5
Long-Term Use of Cardiovascular Drugs S E P T E M B E R 1 5 , 2 0 1 5 : 1 2 7 3 – 8 5
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bias, there is also a need for quality, large-scale
registries.
PROBLEMS WITH CURRENT PRACTICE IN
PRE-LICENSING TRIALS
The RCTs that the pharmaceutical industry un-
dertakes are aimed at getting their products licensed
by regulators, such the Food and Drug Administration
(FDA) and the European Medicines Agency (EMA).
These regulators often require placebo-controlled
trials based on a background of current standard
therapy. Therefore, new cardiovascular medications
are commonly tested on a background of guideline-
recommended therapies that include “standard of
care.” This process leads to polypharmacy because
newly licensed prescription drugs are continually
introduced, whereas older drugs are not commonly
reassessed, and therefore, stay in use. The incre-
mental problems of polypharmacy are emphasized,
particularly in elderly patients.
There is a lack of head-to-head trials in CHD patients
that would offer the opportunity to replace an old drug
with a newer one, rather than continually adding drugs
to the armamentarium. An example of a head-to-head
trial in post-MI patients was VALIANT (Valsartan in
AcuteMyocardial Infarction Trial) (57). This 3-arm trial
randomized patients after an acute MI that was
complicated by heart failure or low ejection fraction to
additional therapy with valsartan, valsartan plus
captopril, or captopril. Valsartan appeared to be as
effective as captopril for overall survival. However,
combining valsartan with captopril increased the rate
of adverse events without improving survival,
demonstrating that the constant addition of drugs is
not always beneﬁcial.
RCTs of ivabradine in both stable CHD and heart
failure patients (58–60) were all placebo-controlled
studies, thus adding ivabradine on top of a beta-
blocker in many patients. Thus, the opportunity for a
head-to-head ivabradine versus beta-blocker compar-
ison was missed, which is disadvantageous because 1
prime feature of both drugs is a reduction in heart rate.
We cannot expect the industry to promote these
head-to-head trials in such a regulatory environment,
because they understandably want the most straight-
forward trial progress to achieve drug licensing.
However, we encourage regulators to take a broader
vision of patient care, recognizing the dangers of
polypharmacy; this could entail a thorough review of
the merits and hazards of the current overall drug
regime each time a new drug is added to the arma-
mentarium (see Responsibilities of Regulators andOther Stakeholders). Regulators might also insist on
more pre-licensing head-to-head trials as an integral
part of enhancing public health needs alongside
commercial interests.
PROBLEMS OF POLYPHARMACY
The decision to prescribe a drug is often on the basis of
a single disease-oriented approach and its associated
guideline recommendations for that speciﬁc drug.
This paradigm of care, which is focused on a speciﬁc
drug–disease link instead of holistic (whole patient)
care, promotes the use of multiple medications by a
patient, a condition known as polypharmacy. This
becomes more complicated because polypharmacy is
increased by the presence of comorbidities, such as
hypertension, chronic obstructive pulmonary disease,
or diabetes, each of which has its own guideline-
recommended drugs.
An American survey of prescribing patterns in the
ambulatory adult population (61) reported the high-
est prevalence of medication use in women older
than 65 years of age, 12% of whom took at least 10
medications and 23% of whom took at least 5 pre-
scription drugs. This trend is increasing dramatically
among older adults in the United States (62), and
cardiovascular drugs represent the most used phar-
macological group in polypharmacy cohorts (63,64).
Among the 20 most commonly used prescriptions in
the United States, 2 are antiplatelet agents (aspirin in
ﬁrst place and clopidogrel is in 18th place), 2 are
statins (atorvastatin in third place and simvastatin in
seventh place), 2 are beta-blockers (metoprolol in
sixth place and atenolol in eighth place), and 2 are
renin–angiotensin system inhibitors (lisinopril in
ﬁfth place and valsartan in 14th place) (64). More-
over, cardiovascular drugs are the most frequent
cause of adverse drug events in ambulatory older
patients (65).
In a Scottish primary care population (66), 21.5%
of adults received at least 4 medications, and 4.6%
received $10 medications. These prevalences in-
creased with age (36.0% and 7.4%, respectively, in
those ages 60 to 69 years, and 70.4% and 18.6%,
respectively, in those ages 80 years or older). Car-
diovascular conditions (e.g., heart failure, ischemic
heart disease, and atrial ﬁbrillation) were associated
with the highest levels of prescribing, which is
consistent with clinical guidelines advocating their
treatment with multiple drug classes.
Polypharmacy increases health care costs and the
risks of noncompliance and of adverse drug reactions,
which is enhanced by both drug–drug and drug–
disease interactions (67).
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1279Fixed-dose combination therapy (the polypill) has
recently been shown to improve adherence in post-MI
patients (19). Its future availability may expose more
patients to polypharmacy. The SECURE (Secondary
Prevention of CardiovascUlaR Disease in the Elderly)
trial is an RCT of the efﬁcacy of the polypill in post-MI
patients, which is about to start recruitment, but it
will be more difﬁcult to assess the impact of long-
term treatment with a polypill on the risk of adverse
events.
There are also concerns regarding the beneﬁt and/or
risk tradeoff for aspirin and statins in primary pre-
vention. In this setting, it has been argued that some
AHA/ACC risk scores may overestimate an individual’s
cardiovascular risk (68), especially among older
people (69). This could result in an excess of people
exposed to drug side effects and more health care
spending. This overestimation may lead to unnec-
essary harms, such as bleeding with aspirin, and less
cost-effectiveness (reduced absolute beneﬁt) of pri-
mary prevention interventions, such as statins (13).
LONG-TERM USE OF
MEDICATIONS AND AGING
At present, 13% of the American population is ages
65 years or older, and this will rise to approximately
20% by 2030 (67). People ages 85 years and older are
the most rapidly growing segment of the U.S. popu-
lation and will include 18% of those ages 65 years or
older by 2040. In the United Kingdom, people ages
65 years and older will account for 23% of the popu-
lation by 2035 (70). The fastest increase is occurring
among the very old (age 85 years and older); between
1985 and 2010, this population more than doubled.
Aging is often accompanied by both comorbidities
and frailty, and consequently leads to potentially
excessive polypharmacy.TABLE 3 Common Side Effects and Interactions of Aspirin, Statins, B
Drug Class Side Effects in Older Patients
Aspirin Gastrointestinal bleeding, dyspepsia,
tinnitus, skin reactions
Asthma (
Gastroint
and h
Statins Myalgias, confusion, renal insufﬁciency,
liver toxicity
Hypothyr
(stati
Beta-blockers Confusion, fatigue, bronchospasm,
conduction block, claudication,
depression, incontinence, hypoglycemia
COPD (b
PAD (inte
Raynaud
CHF (acu
Conducti
ACE inhibitors Falls, dizziness, hypotension, hyperkalemia,
fatigue, acute kidney injury, cough
CKD (hyp
COPD ¼ chronic obstructive pulmonary disease; NSAID ¼ nonsteroidal anti-inﬂammatorPhysiological aging changes both the pharmacoki-
netics and pharmacodynamics of cardiovascular drugs
(70). Pharmacokinetic changes include a reduction
in renal and hepatic clearance and increased body
fat, leading to altered distribution, metabolism, and
elimination of cardiovascular drugs (particularly
beta-blockers and ACE inhibitors). Pharmacokinetic
changes also increase the risk of statin-related adverse
events in older adults, including cognitive impair-
ment, falls, neuropathy, and muscle damage (13).
The pharmacodynamics of cardiovascular drugs are
affected by age-related changes in end-organ respon-
siveness (67,71). Therefore, alterations to both sinus
node activity and atrioventricular conduction in the
elderly may lead to increased sensitivity to the bra-
dycardic effect of beta-blockers.
In addition, the elderly experience more com-
orbidities, and the drugs used to treat them increase
the risk of drug–disease and drug–drug interactions
(Table 3). As a drug–disease interaction, beta-blocker
treatment can cause intermittent claudication in pa-
tients with peripheral vascular disease and broncho-
constriction in the presence of chronic obstructive
pulmonary disease. A drug–drug interaction can occur
when ACE inhibitors and potassium-sparing diuretics
cause hyperkalemia, or when simultaneous use of
statins and other lipid-lowering agents, such as gem-
ﬁbrozil and niacin, result in rhabdomyolysis and acute
renal failure. ACE inhibitors may interact with
co-trimoxazole, increasing the risk of sudden death
(72). In the same way, ACE inhibitors and aspirin may
interact with common medications, such as nonste-
roidal anti-inﬂammatory drugs, resulting in hyper-
kalemia and peptic ulceration, respectively (73).
In making treatment decisions in the elderly, clini-
cians should take into account the limited external
validity of RCTs (74)—can the results of a particular
treatment after MI be reasonably applied to the elderlyeta-Blockers, and ACE Inhibitors in the Elderly
Drug–Disease Interactions Drug–Drug Interactions
bronchospasm)
estinal bleeding history, dehydration,
ypertension (bleeding)
Anticoagulants, antiplatelets and antithrombins
(bleeding)
NSAIDs (peptic ulcer)
oidism, CKD, diabetes mellitus
n-induced myopathy)
Fibrates (myopathy)
Amiodarone, erythromycin, diltiazem, azole antifungals,
ﬁbric acids (P450 system interactions)
ronchospasm)
rmittent claudication)
syndrome (increased symptoms)
te decompensation)
on disease (heart block)
Sulfonylureas (hypoglycemia)
Calcium-channel blockers (chronotropic
incompetence)
erkalemia and renal failure) Diuretics (hypotension)
NSAIDs (renal failure)
y drug; PAD ¼ peripheral artery disease; other abbreviations as in Table 1.
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represented in RCTs as a consequence of exclusion
criteria and under-recruitment (56). In routine prac-
tice, the median age of patients presenting with a ﬁrst
MI is 70 years, and patients ages 75 years or older ac-
count for 36% of all MIs (67). However, only 7% of all
patients enrolled in ACS trials between 1966 and 2000
were 75 years of age or older (75). Moreover, because of
the short duration of RCTs, too few patients are fol-
lowed into older age; therefore, there is inadequate
testing of drug efﬁcacy and safety in the elderly. Some
key studies fail to demonstrate beneﬁt in the elderly. In
a meta-analysis of post-MI patients who received an
ACE inhibitor, no survival beneﬁt was found in pa-
tients ages 75 years or older (16).
Most drug RCTs focus on the reduction of “hard”
clinical outcomes, whereas less attention is paid to
symptom relief and quality of life, which might be of
greater concern among the elderly.
Better evidence is needed on the effectiveness and
potential harms of drugs in older adults, who tend
to have multiple chronic conditions and who are
sometimes frail.
DEPRESCRIBING
Discontinuing drug treatments, or deprescribing, is
the process of withdrawing drugs in an attempt
to improve patients’ outcomes (76). Deprescribing
involves establishing which drug does not have a
current indication or may be causing a problem. In
contrast to prescribing practices, the deprescribing
process is not represented in guidelines and is usually
based on clinical judgment. Although prescribing
drugs is substantially based on evidence from RCTs,
the rationale for discontinuation of drugs is inade-
quately addressed by RCTs, as discussed in the
following section. This issue is crucial in older adults,
who are the largest per capita consumers of pre-
scription medications and the most vulnerable
population for medication adverse effects and in-
teractions, partly as consequence of polypharmacy.
At present, deprescribing receives insufﬁcient
attention, and there is a great need for the depres-
cription process to be based on objective evidence
rather than solely on subjective clinical judgment.
THE NEED FOR TRIALS ON
WITHDRAWAL OF DRUGS
The possibility that cardiovascular drugs may have
reduced efﬁcacy over longer medication periods is an
important issue that has received little attention.
Likewise, the potential long-term harm of these
drugs, enhanced by an accumulating polypharmacy,especially in elderly patients, still needs to be
addressed. Clinical trials aimed at investigation of the
withdrawal of certain established medications are
needed to cover both these long-term efﬁcacy and
safety issues (77).
One major problem in undertaking such trials
investigating withdrawal of a drug is the difﬁculty of
funding them. Once a drug has achieved regulatory
approval, company sponsors do not routinely plan
any long-term efﬁcacy and safety assessment. Also, it
is clearly not in their commercial interests to inves-
tigate any timely withdrawal of their drugs. Thus,
evidence is relegated to post-licensing surveillance,
with its inevitable biases, absence of efﬁcacy data,
and inadequate detection of adverse effects. Conse-
quently, the deprescribing process receives little help
from current guidelines or clinical trials, and any
decisions on withdrawal of drugs are largely ad-hoc
and on the basis of individual clinical judgment.
The regrettable lack of drug withdrawal trials has
to be improved to provide objective guidance on the
long-term use and potential withdrawal of drugs. One
notable exception concerns trials into the timing of
withdrawal of dual antiplatelet therapy after PCI
(78,79). Their challenge of counterbalancing the risks
of ischemic events (stent thrombosis and MI) and
bleeding events is a paradigm of the tradeoff between
efﬁcacy and safety assessment, and a good illustra-
tion of how to get trials of treatment withdrawal on
the research agenda.
Limited observational data are available describing
the clinical impact of drug withdrawal after MI (80).
There is no good evidence base for the continuation
of aspirin, statins, beta-blockers, and ACE inhibitors
in the long term, and further investigation is needed.
Drug discontinuation is sometimes associated with
a rebound phenomenon, which might complicate how
to design a drug withdrawal trial. Thus, abrupt beta-
blocker withdrawal may be associated with an
increased risk for acute MI and sudden death (8).
Consequently, the drug should be tapered down over
a 1- to 3-week period. In the same way, abrupt statin
withdrawal may lead to an inﬂammatory rebound
process (80). Other publications have suggested a
potential increased thrombotic risk following anti-
platelet therapy withdrawal (81), whereas a hyper-
tensive rebound phenomenon after ACE inhibitor
withdrawal is more controversial.
We wish to encourage an active debate that will lead
to action in the planning and execution of RCTs of
withdrawal of cardiovascular drugs that are currently
in long-term use. There are many questions to be
posed. First, which drugs are ripe for such investiga-
tion? Here, we propose beta-blockers as a prime case
FIGURE 1 Design of a Large Simple Beta-Blocker Withdrawal Trial
Patient undergoes
PCI and/or
has an MI 6 months
Randomize
those on 
beta-blocker*
Withdraw
beta-blocker
Continue on
beta-blocker
1 year
1 year
Composite primary
endpoint: death,
MI and HF
hospitalization
Extended
follow-up
Extended
follow-up
Design of a randomized clinical trial for withdrawal of beta-blockers in stable coronary heart disease patients. *Exclude patients requiring beta-blockers due to other
reasons. HF ¼ heart failure; MI ¼ myocardial infarction; PCI ¼ percutaneous coronary intervention.
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1281(see the following section). Next, at which point in
follow-up after which initial disease event do we pro-
pose patients be randomized to drug withdrawal or
continuation? Exactly which patients will be eligible
and how will they be identiﬁed? In the longer term,
patient management may take place more with pri-
mary care physicians than with cardiologists, so
how to achieve reliable follow-up requires careful
consideration. Another challenge is the choice of
primary and secondary endpoints, covering both the
efﬁcacy and safety aspects of drug withdrawal and/or
continuation.
AN EXAMPLE RCT FOR WITHDRAWAL
OF BETA-BLOCKERS
The ﬁrst RCTs of beta-blockade in secondary preven-
tion after MI were published in the 1960s, and all such
trials took place before primary PCI became routine
practice. Beta-blocker therapy after successful pri-
mary PCI has not been studied in RCTs, but a non-
randomized comparison shows that this therapy is
associated with lower 6-month mortality (51). How-
ever, there is little evidence of continued efﬁcacy and
safety for the long-term use of beta-blockers in stable
CHD (although it is common practice), and this prob-
lem should be addressed by a randomized controlled
drug withdrawal study. The design essentials of such
an RCT are discussed in the following (Figure 1).
First, the eligibility criteria should encompass a
broad spectrum of patients with stable CHD, with
special attention paid to those who have had a MI,
which would form a pre-speciﬁed subanalysis.
Patients who take beta-blockers due to the presence
of documented arrhythmias, chronic heart failure,
and refractory angina would need to be excluded,
because withdrawal would be contrary to recom-
mended guidelines and established patient beneﬁt.Second, randomization to continuation or with-
drawal (using a tapering of dose according to good
standard practice) would take place 6 months after a
coronary event in post-MI patients or revasculariza-
tion in stable patients, in the spirit of identifying
patients at a routine post-procedure follow-up visit.
Because of the need for tapering and screening for
any side effects, assignment could not realistically be
double-blinded.
Third, the composite primary endpoint could be
all-cause death, MI, and hospitalization for heart
failure over a 1-year follow-up, which could be pow-
ered for a noninferiority hypothesis, but also assessed
for superiority. A potential further hypothesis could
focus on speciﬁc subgroups (e.g., the elderly, post-MI
patients) and also on longer term follow-up, if this
could be maintained.
Secondary endpoints could include hospitalizations
for ACS and repeat revascularization procedures. In
addition, quality of life and angina symptoms could
be obtained (perhaps by telephone interviews at
4months and 1 year). Compliance data on beta-blocker
use (or not) should also be collected during these
interviews. Safety endpoints would include side
effects and interactions attributable to beta-blocker
therapy (e.g., atrioventricular block).
Any drug withdrawal trial with a major adverse
cardiac events-type primary endpoint needs to be as
large as placebo-controlled trials of drug efﬁcacy,
which could be a problem. Hence, with a hazard ratio
noninferiority margin of 1.3, to achieve 80% power,
requires approximately 450 patients overall to reach
the primary composite endpoint. Thus, the trial
would need to recruit several thousand patients.
Clearly, this would need to be a large, simple, prag-
matic trial with limited data collection.
Can such a drug withdrawal RCT be funded and
conducted? Is there the collective will to make such a
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needed ﬁrst to establish that such a trial is delineable.
However, the essential message is that without
such trials of treatment withdrawal, there will con-
tinue to be no evidence base to determine which
long-term therapies are beneﬁcial to patients, and
which are neutral or even harmful.
RESPONSIBILITIES OF REGULATORS
AND OTHER STAKEHOLDERS
At present, regulatory authorities such as the FDA
and EMA do not directly engage with many of the
issues tackled in this review. Drugs are licensed on
the basis of evidence of efﬁcacy and safety from
relatively short-term follow-ups in RCTs of selected
populations. Post-licensing studies, whether RCTs or
observational registries, are often requested to eval-
uate drug safety in more real-world populations, but
they too are of limited duration.
Thus, concerns regarding long-term use of multiple
cardiovascular (and other) drugs, especially in the
elderly and patients with comorbidities, do not
appear within the remit of regulators. So should their
current focus on adding each individual new licensed
drug on the basis of relatively short-term patient
beneﬁt on top of standard of care, now be expanded
to the broader concept of “whole patient long-term
care”? Were this increased responsibility to happen,
regulators could then commission the types of RCTs
and pharmacoepidemiological studies that would
yield an evidence base that would be truly pertinent
to real-world, long-term patient care.
The professional societies, such as the ACC/AHA
and the European Society of Cardiology, have done
an excellent job in producing very informative
treatment guidelines that have enhanced day-to-day
cardiology patient management. However, they
have also not seriously grappled with the long-term
use of multiple cardiovascular drugs, admittedly
because of the lack of good evidence. Because of the
importance of these issues, we encourage these so-
cieties to train working partners, and to begin
research studies (and their funding) and other ac-
tions that could ultimately lead to evidence-based
guidelines on long-term drug use. Of course, this
would also require the research community in clin-
ical cardiology to have a collective “wake-up call” in
pursuing pertinent projects, both interventional and
observational, on areas such as polypharmacy in the
elderly.
Health care providers, such as the U.K. National
Health Service, also need to consider how they can
enhance more rigorous monitoring of individualpatients’ long-term drug use. For instance, could they
mandate that each patient on polypharmacy (e.g., $5
drugs) have regular (annual) reviews of their drug
use by their primary treating physician, with a view
to making sound decisions on whether any of them
could be withdrawn. This would be particularly
important in the elderly, where concerns about
noncompliance also matter.
All treating physicians, both cardiologists and
others (e.g., primary care) need to avoid the trap of
routine repeat-prescribing over many years, regard-
less of whether this is in the patient’s best interests.
A better awareness of potential side effects, espe-
cially in the context of older age polypharmacy, is
much needed. Also, those initiating drug use (e.g.,
cardiology consultants) may well be different from
those handling long-term care (e.g., general practi-
tioners). A closer dialogue across specialties is needed
to ensure that a patient’s total drug use, including
deprescribing, is handled wisely.
Lastly, patients themselves should be encouraged
to participate in decisions relating to their long-term
therapy.
RECOMMENDATIONS
We conclude with a set of recommendations that
relate both to a future research agenda and to im-
provements in patient care:
1. The gap in knowledge regarding the long-term
efﬁcacy and safety of cardiovascular drugs needs
wider recognition.
2. The untested assumption that short-term drug
beneﬁt over a few years post-MI extends into
long-term follow-up and older age needs to be
challenged.
3. The trial evidence for beta-blockers, which began
before the introduction of primary PCI, is
outdated, meaning their role particularly needs to
be questioned.
4. We need to encourage more RCTs to continue into
long-term follow-up, and to reﬂect real-world
practice, such as including increased numbers of
older patients.
5. Regulatory placebo-controlled trials tend to lead
to a growing plethora of approved drugs, so a
new paradigm (e.g., more head-to-head trials) is
needed.
6. The problems of polypharmacy need to be
tackled.
7. Deprescribing should be considered more often,
and requires more objective evidence for its
practice.
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12838. RCTs that study withdrawal of long-term medi-
cation are needed; the case for a withdrawal trial
of beta-blockers is particularly pertinent.
9. More research on the effectiveness and potential
harms of cardiovascular drugs is needed in older
patients, who often have comorbidities and are
sometimes are frail.
10. Regulators, professional societies, the cardiology
research community, and health care providers all
need to engage with these problems of long-term
prescribing of multiple drugs.11. Both cardiologists and primary care physicians
should pay greater attention to each patient’s
long-term needs, for example, by regularly re-
viewing whether multiple long-term medications
are truly of beneﬁt.
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